Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer

Inclusion Criteria: * Histologically/cytologically confirmed unresectable locally advanced pancreatic adenocarcinoma. * Measurable disease by RECIST criteria must be present. * Karnofsky Performance Status ≥ 70 * Patients with adequate organ functions reflected by the laboratory criteria below: Granulocytes ≥ 1,500/uL Hemoglobin ≥ 8.0 gm/dL Platelets ≥ 100,000/uL Serum creatinine \< 2.0 mg/dL Bilirubin \< 1.5 mg/dL SGPT \< 2.5 x normal Alk Phos \< 2.5 x normal * Prior local therapy, e.g., radiation, is allowed provided that at least 4 weeks washout time is given. * Patients with jaundice must have a biliary drainage decompression operation before recruitment. * Patients must not be pregnant. Serum beta-HCG will be checked in all premenopausal patients. * Ability to understand and the willingness to sign a written informed consent. Exclusion Criteria: * Subject with metastatic disease. * Prior treatment with systemic chemotherapy. * Known allergies to the gemcitabine, oxaliplatin or iodine contrast agent. * Subject with Child-Pugh grade Class C hepatic impairment, active gastrointestinal bleeding, severe coagulation disorder that could not be corrected，or other contraindication for transcatheter infusion. * Untreated or uncontrolled deep vein thrombosis, arterial thrombosis of lower extremity, or aneurysm. * Concurrent infection requiring intravenous antibiotics. * Skin injury or infection of groin area, or other situation that not appropriate for femoral artery puncture. * Other serious illness or condition including cardiac disease including congestive heart failure (New York Heart Association Classification III or IV), active HIV infection/HIV disease, psychiatric disorders. * Known central nervous system involvement and leptomeningeal disease * Subject with previous or concurrent cancer that is distinct in primary site or histology from pancreatic adenocarcinoma except cervical carcinoma in situ, non-melanoma carcinoma of the skin or in situ carcinoma of the bladder. Any cancer curatively treated greater than 3 years prior to entry is permitted. * Pregnant or lactating women.